Furthermore, knowing that SHIP2 is upregulated in several types of cancer and that this correlates with decreased patient survival, raises an intriguing question whether SHIP2 inhibitors could provide potential means also for new personalized treatment options for cancer patients. Here, INPPL1 is linked to cancer.